Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

2010/10/22 by William J. Marks, William J Marks, Raymond T. Bartus +44 · 3 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Adverse effect #Clinical endpoint #Clinical trial #Consolidated Standards of Reporting Trials #Glial cell line-derived neurotrophic factor #Internal medicine #Medicine #Nerve injury and regeneration #Neurotrophic factors #Neurturin #RNA Interference and Gene Delivery #Randomized controlled trial #Surgery #Virus-based gene therapy research

paper · doi:10.1016/s1474-4422(10)70254-4

openalex publication_date 2010/10/22 · crossref created 2010/10/22 · crossref issued 2010/12/01 · crossref published 2010/12/01 · crossref published-print 2010/12/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/26 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31

Citations

• The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score
• The MOS 36-ltem Short-Form Health Survey (SF-36)

Cited by

• Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions
• Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention
• Management of Parkinson's disease [wikipedia]